Sera Prognostics Joins ARPA-H Funded Project to Develop Fetal Hypoxia Diagnostic
Event summary
- Sera Prognostics collaborates on a $10.4M ARPA-H award to develop a point-of-care diagnostic for fetal hypoxia risk assessment.
- The project is part of ARPA-H's Making Obstetrics Care Smart (MOCS) program, led by UC San Diego.
- Sera will contribute its expertise in protein biomarker discovery and validation.
- The goal is to create a rapid testing platform using maternal blood samples to guide clinical decisions during labor.
The big picture
This collaboration underscores a broader shift toward proactive risk identification in maternal health, moving away from reactive approaches. The project aligns with growing interest in biomarker-driven diagnostics to address persistent challenges in obstetrics care. Sera's involvement highlights its strategic focus on expanding its diagnostic pipeline beyond preterm birth prediction.
What we're watching
- Technical Feasibility
- Whether Sera can successfully integrate biomarkers into a rapid point-of-care testing platform.
- Market Adoption
- The pace at which innovative diagnostics gain acceptance in obstetrics care.
- Regulatory Pathway
- How FDA regulations may impact the development and approval of new diagnostic technologies.
Related topics